Ryman Healthcare Limited (RYM) fair value: what the stock is really worth
As of Nov 11, 2026: fair value (intrinsic value) of Ryman Healthcare Limited stock A$1.67, price A$1.53, upside +9.8%, quality 42 out of 100. Rating: fairly valued. Calculated from audited financials with 9 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.
How to read this chart
13‑month range A$1.35 – A$2.61 · fair‑value band A$0.6545 – A$3.03 · the A$1.53 price screens below the A$1.67 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 8, 2026.
Follow Ryman Healthcare in your weekly email
Every Wednesday you see whether Ryman Healthcare is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Ryman Healthcare Limited develops, owns, and operates integrated retirement villages, rest homes, and hospitals for the older people in New Zealand and Australia.
Show moreShow less
The company's villages provide apartments and townhouses, and assisted-living in serviced apartments, and care center, which offers rest homes, hospitals, specialist dementia care, and respite care services. Ryman Healthcare Limited was founded in 1984 and is based in Christchurch, New Zealand.
Stock analysis
Ryman Healthcare Limited (RYM) currently trades at A$1.53, while our model-based Fair Value estimate is A$1.67, so the stock looks roughly fairly valued today (gap 8.9%).
Show more
Valuation
Bull case: the Growth DCF group reads highest at a median of A$3.43 per share, and 6 of the 9 models we run sit above the A$1.53 price.
Bear case: the Multiples group reads lowest at A$0.6600, and 3 of the 9 models stay below the price. Data coverage for this calculation is medium.
Scenario range: A$0.6545 (bear) to A$3.03 (bull), the price of A$1.53 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 42/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Ryman Healthcare Limited reported revenue of 804M NZD in FY2026 versus 504M NZD in FY2022, a compound +12.4%/yr. Reported net income was −173M NZD in FY2026.
Key figures
Market cap A$1.5B (≈ $1.1B) Small · P/S ratio 1.72 · EPS (TTM) A$−0.5500 · Net margin −21.5% · Return on equity −4.2% · Return on assets (EBIT) −0.4% (5-year average) · Operating margin 5.3% · Revenue (TTM) 854M NZD.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 17 out of 100 (low confidence).
What moves the price
The share trades about 42% below its 52-week high and 13% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −4% fair-value upside, at 10%, RYM screens cheaper than that median.
Fair Value models
BearA$0.6545Fair Value A$1.67BullA$3.03
Price A$1.53 · Upside +9.8%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCFA$2.31A$5.24A$10.2275
Growth DCFA$2.26A$4.86A$9.0874
5Y Revenue ExitA$0.7700A$1.99A$3.5968
All 9 models by family
DCF Models
FCF DCFA$2.31A$5.24A$10.2275
5Y Revenue ExitA$0.7700A$1.99A$3.5968
5Y EBITDA Exitn/aA$0.3800A$0.770067
10Y Revenue ExitA$1.23A$2.56A$4.5264
10Y EBITDA ExitA$0.7700A$1.41A$2.2067
Multiples
EV/RevenueA$0.0800A$0.6600A$1.2447
Asset-Based
NCAV (Graham)A$1.64A$2.20A$3.2854
Growth DCF
Growth DCFA$2.26A$4.86A$9.0874
Rev-Margin DCFA$0.7700A$1.99A$3.6168
The fair value above starts from this blend and is adjusted for dilution from new shares.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.63/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+12.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.3%
Start year 2021 (pandemic). Over 10 years: +11.9% a year
Revenue growth 19 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+14.4%
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
’26
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
12.3% (2021) → −2.2% (2026)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2026 is a loss year, no rate is defined from a loss
not computed
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far and less than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+2.1%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+8.6%
Yearly sales growth analysts expect, extended to five years.
After inflation (figures in NZD, New Zealand: IMF forecast 2.3% a year to 2030, 3.0% from 2016 to 2025) that is about −0.2% a year for the price and +6.2% for the forecasts.
Compare Ryman Healthcare Limited with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 246 stocks
Beats the industry median on 4/11 measures
Overall it trails its industry peers.
Valuation
Quality Score42 · Bottom 25%
Fair Value upside+9.8% · Above median
Profitability
Return on assets−1.4% · Bottom 25%
Net margin (12 months)−20.1% · Bottom 25%
Operating margin (12 months)5.3% · Below median
Growth and dividend
Revenue growth (quarter YoY)11.9% · Above median
Balance sheet
Debt / equity0.41× · Above median
Valuation Multiplesvs Medical Care Facilities median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Ryman Healthcare Limited (RYM) overvalued or undervalued?
As of Nov 8, 2026, our model estimates a fair value of A$1.67 versus a price of A$1.53, about +10% upside (fairly valued).
What is the fair value of RYM?
Our model-based fair value for Ryman Healthcare Limited is A$1.67 (as of Nov 8, 2026), built from audited fundamentals. The current price: A$1.53.
What is the quality score of RYM?
Ryman Healthcare Limited has a Quality Score of 42/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Ryman Healthcare Limited (RYM)?
Our model-based price target is the fair value of A$1.67 (as of Nov 8, 2026) from 9 valuation models. Cautious scenario A$0.6545, optimistic scenario A$3.03. It is a calculation from audited fundamentals, not an analyst target.
What is the Ryman Healthcare Limited stock forecast for 2026?
Our models put fair value at A$1.67, about +10% upside versus a price of A$1.53 (fairly valued). Cautious scenario A$0.6545, optimistic scenario A$3.03. The calculation is refreshed regularly with new filings.
What is the revenue of Ryman Healthcare Limited (RYM)?
Ryman Healthcare Limited reported trailing-twelve-month revenue of about 854M NZD (latest available figure, as of Nov 8, 2026).
What growth is priced into Ryman Healthcare Limited (RYM)?
For today's price to be fair in a discounted-cash-flow model, Ryman Healthcare Limited would have to grow free cash flow by +2.1 % per year for five years (discount rate 9.6 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +12.4 % per year. As of Nov 8, 2026.
What discount rate (WACC) does the fair value of RYM use?
Our models discount Ryman Healthcare Limited at 9.6 %: a base by market capitalisation (small), damped by beta 0.37, country premium for Australia. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Ryman Healthcare Limited that is +2.1 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (9.6 %) and the same formula as our fair value.
How much growth has Ryman Healthcare Limited (RYM) delivered so far?
Over the past 5 years revenue at Ryman Healthcare Limited grew +12.4 % a year. The price currently implies free-cash-flow growth of +2.1 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Ryman Healthcare Limited (RYM) growing?
The median revenue growth in the sector is +1.6 % a year. That is the yardstick for the growth priced into Ryman Healthcare Limited (+2.1 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Ryman Healthcare Limited (RYM)?
The free-cash-flow yield on the price is 14.45 %: that much free cash flow Ryman Healthcare Limited produces per unit of market value. When it exceeds the discount rate of our models (9.6 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Ryman Healthcare Limited (RYM)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Ryman Healthcare Limited it is A$1.67 per share (as of Nov 8, 2026), against a price of A$1.53. It is the blended result of 9 valuation models in 4 families (DCF Models, Multiples, Asset-Based, Growth DCF).
Is Ryman Healthcare Limited stock overvalued or undervalued in 2026?
As of Nov 8, 2026, RYM trades below its calculated fair value: price A$1.53, fair value A$1.67, a gap of about +10% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of RYM?
No. The price is what the market pays today (A$1.53); the fair value is what the company's own numbers justify (A$1.67). For Ryman Healthcare Limited the two are A$0.1495 per share apart. That gap is exactly why we show both numbers side by side.
How much is Ryman Healthcare Limited worth?
The market values Ryman Healthcare Limited at about A$1.5B (market capitalisation, as of Nov 8, 2026). Per share that is A$1.53; our models calculate a fair value of A$1.67 per share.
What do the bullish and bearish scenarios say about RYM?
Our models span a range for Ryman Healthcare Limited: cautious scenario A$0.6545, base A$1.67, optimistic A$3.03 per share (as of Nov 8, 2026, price A$1.53). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Ryman Healthcare Limited (RYM)?
Balance-sheet figures for Ryman Healthcare Limited (as of Nov 8, 2026): return on equity −4.2%, debt of 0.41 per unit of equity. They feed the Quality Score of 42/100, which measures business quality independently of the share price.
How far is RYM from its 52-week high?
Ryman Healthcare Limited trades at A$1.53, about 42% below its 52-week high of A$2.61 and 13% above the low of A$1.35 (as of Nov 11, 2026). Distance from the high says nothing about value: that is what the fair value of A$1.67 is for.
Which stocks are comparable to Ryman Healthcare Limited?
From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Tenet Healthcare Corporation, Dr. Sulaiman Al Habib Medical Services Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Ryman Healthcare Limited stock attractive at the current price?
The data as of Nov 8, 2026: price A$1.53, calculated fair value A$1.67 (+10%), Quality Score 42/100, from 9 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of RYM calculated?
We run Ryman Healthcare Limited through 9 models from 4 families: DCF Models, Multiples, Asset-Based, Growth DCF. Every model gets the same audited fundamentals; the fair value of A$1.67 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Ryman Healthcare Limited currently trades 9% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Ryman Healthcare Limited (RYM)?
The closing price on Nov 11, 2026 was A$1.53. Our model-based fair value is A$1.67, about +10% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Ryman Healthcare Limited right now?
The model range is unusually wide (A$0.6545 to A$3.03). The outcome hinges heavily on assumptions, so read the point estimate with caution. The price sits close to our fair value, market and models broadly agree here, little valuation tension.
Key figures of Ryman Healthcare Limited
How large is the market capitalisation of Ryman Healthcare Limited (RYM)?
The market capitalisation of Ryman Healthcare Limited is A$1.5B (≈ $1.1B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Ryman Healthcare Limited (RYM)?
The price-to-sales ratio of Ryman Healthcare Limited is 1.72 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Ryman Healthcare Limited (RYM)?
Earnings per share at Ryman Healthcare Limited are A$−0.5500. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Ryman Healthcare Limited (RYM)?
The net margin of Ryman Healthcare Limited is −21.5% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Ryman Healthcare Limited (RYM)?
The return on equity (ROE) of Ryman Healthcare Limited is −4.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Ryman Healthcare Limited (RYM)?
On an EBIT basis the return on assets of Ryman Healthcare Limited is −0.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Ryman Healthcare Limited (RYM)?
The operating margin of Ryman Healthcare Limited is 5.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Ryman Healthcare Limited (RYM)?
Revenue at Ryman Healthcare Limited is growing +11.9% versus a year earlier (3y avg +12.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much net debt does Ryman Healthcare Limited (RYM) carry?
The net debt of Ryman Healthcare Limited is 1.6B NZD (fiscal year 2026, ≈ 5.8 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Ryman Healthcare Limited in the live analysis
One click puts Ryman Healthcare Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Some data
Nov 8, 2026